# Platelet-rich plasma improves pain and function in knee osteoarthritis: a retrospective study

## TL;DR

This study found that platelet-rich plasma injections can reduce knee pain and improve function in people with osteoarthritis, with injection count and BMI being key factors.

## Contribution

The study identifies specific factors influencing PRP treatment outcomes for knee osteoarthritis, offering guidance for optimizing clinical protocols.

## Key findings

- PRP injections significantly reduced pain and improved function in knee osteoarthritis patients over six months.
- The number of PRP injections was the only factor significantly affecting pain outcomes.
- BMI and disease duration were significant predictors of functional improvement in WOMAC scores.

## Abstract

This study aimed to evaluate the efficacy of platelet-rich plasma (PRP) in treating knee osteoarthritis (KOA) and the effects of baseline characteristics and PRP intervention parameters on treatment outcomes.

Overall, 140 individuals diagnosed with KOA who received PRP injections and completed a 6-month follow-up period were enrolled in this retrospective analysis. Knee pain and functional outcomes were assessed using the Visual Analog Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Based on the Minimal Clinically Important Difference (MCID) in outcomes, the participants were divided into effective and ineffective groups. Using multivariable logistic regression to explore factors influencing treatment outcomes, we compared the effective and ineffective groups to identify predictors of response to PRP therapy.

At 6 months, the median (IQR) VAS score significantly decreased from 66.5 (27) to 24 (34) (95% CI = −38 to −30.5), p < 0.001), and WOMAC scores improved from 29 (22) to 12 (14) (95% CI = −16.5 to −12), p < 0.001). Five mild adverse events were reported. Multivariate analysis indicated that only the number of injections significantly influenced VAS outcomes (OR = 4.285, 95% CI: 1.586–11.578, p = 0.004). Regarding WOMAC, multivariate analysis revealed that body mass index (BMI) (OR = 0.867, 95% CI: 0.755–0.995, p = 0.042) and disease duration (OR = 0.905, 95% CI: 0.784–0.989, p = 0.045) significantly affected outcomes. Age, sex, Kellgren-Lawrence (KL) grade, number of PRP injections, and injection frequency did not significantly impact WOMAC scores.

PRP therapy is a safe and effective treatment option for KOA. In this 6-month follow-up investigation, we observed that the number of injections administered affected pain levels, while disease duration and BMI affected knee joint function. Insights from this study may facilitate patient selection and PRP treatment protocol optimization in clinical practice.